Clinical Trials Browser

Phase 2 × Myelodysplastic Syndromes × olaparib × Clear all

NCT03953898 2025-09-10

Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation

Phase 2 Active not recruiting

14 enrolled 12 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute